Evidence map›Paper›PMID 35087233›Full record

Trial reportNature medicine2022

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.

Jingxin Li, Lihua Hou, Xiling Guo, Pengfei Jin, Shipo Wu, Jiahong Zhu, Hongxing Pan, Xue Wang, Zhizhou Song, Jingxuan Wan and 11 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IVRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04892459 (Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine), which is not on this map. Cited by 91 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 8 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04892459 phase4completednot on this map

Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial

TypeinterventionalSponsorJiangsu Province Centers for Disease Control and PreventionRan2021 to 2021Enrolled300ConditionsCOVID-19ArmsRecombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell)
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 8 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Jingxin Li *NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Lihua Hou *Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China.ORCID http://orcid.org/0000-0001-7366-8974
Xiling Guo *NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Pengfei Jin *NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Shipo WuInstitute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China.ORCID http://orcid.org/0000-0001-8083-247X
Jiahong ZhuLianshui County Center for Disease Control and Prevention, Lianshui County, P. R. China.
Hongxing PanNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Xue WangCanSino Biologics Inc., Tianjin, P. R. China.
Zhizhou SongLianshui County Center for Disease Control and Prevention, Lianshui County, P. R. China.
Jingxuan WanCanSino Biologics Inc., Tianjin, P. R. China.
Lunbiao CuiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Junqiang LiCanSino Biologics Inc., Tianjin, P. R. China.
Yin ChenNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Xuewen WangCanming Medical Technology Co., Ltd, Shanghai, P. R. China.
Lairun JinDepartment of Public Health, Southeast University, Nanjing, P. R. China.
Jingxian LiuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Fengjuan ShiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
Xiaoyu XuVazyme Biotech Co., Ltd, Nanjing, P. R. China.
Tao ZhuCanSino Biologics Inc., Tianjin, P. R. China.
Wei ChenInstitute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China. cw0226@foxmail.com.ORCID http://orcid.org/0000-0001-5805-2469
Fengcai ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China. jszfc@vip.sina.com.ORCID http://orcid.org/0000-0002-1644-0006
Jiangsu Provincial Center for Disease Control and Prevention · CNCanSino (China) · CNAcademy of Military Medical Sciences · CNChina Pharmaceutical University · CNSoutheast University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82173584
6 · The paper itself

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3-6 months were vaccinated with Convidecia (n = 96) or CoronaVac (n = 102). Adults who had received one dose of CoronaVac in the past 1-3 months were also vaccinated with Convidecia (n = 51) or CoronaVac (n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.

Indexed as

AdenoviridaeAdolescentAdultAntibodies, NeutralizingAntibodies, ViralChinaCOVID-19COVID-19 VaccinesFemaleHumansImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInjection Site ReactionMaleMiddle AgedAd5-nCoV vaccineAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GVaccines, Inactivated

Identifiers

PMID35087233
PMCPMC8863573
OpenAlexW4210704633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.